Drug Trial Radar · NCT05418868
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
214
Planned (sponsor's estimate)
Start
Jun 14, 2022
Primary completion
Mar 31, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline; Janssen Sciences Ireland Unlimited Company
- First posted
- Jun 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, dose-escalation study to investigate the safety, tolerability and pharmacokinetics (PK) of single subcutaneous (SC) administration of long acting (LA) Cabotegravir (CAB) 200 milligrams per milliliter (mg/mL) with Recombinant Human Hyaluronidase PH20 (rHuPH20) (Part A), a single-dose or repeat-dose SC or intramuscular (IM) administration of LA CAB (greater than or equal to) \>=400 mg/mL (Part C), single-dose IM administration of LA CAB Formulation I (Part C Cohort C8) and LA CAB Formulation J (Part C Cohort C11), and a single-dose or repeat-dose IM administration of rilpivirine (RPV) (Part E). Part A of the study (CAB 200 mg/mL with rHuPh20) has been closed to further enrolment based on preliminary results. Part D of the study (CAB \>=400 mg/mL with rHuPH20) will not be conducted due to changes in the study design.
Conditions
- HIV Infections
Interventions
Cabotegravir 200 mg/mLDrug
CAB 200 mg/mL will be administered.
CAB >=400 mg/mLDrug
CAB \>=400 mg/mL will be administered by IM or SC injection.
CAB Formulation IDrug
CAB Formulation I will be administered by IM injection.
CAB Formulation JDrug
CAB Formulation J will be administered by IM injection.
rHuPH20Drug
rHuPH20 will be administered.
RPVDrug
RPV will be administered by IM injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax) of CAB and RPVTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Time of maximum observed plasma concentration (tmax) of CAB and RPVTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Area under the concentration - time curve from time zero to infinity (AUC[0-inf]) of CAB and RPVTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Area under the concentration - time curve from time zero to time of last quantifiable concentration or 4 weeks following the injection whichever is earlier (AUC[0-t]) of CAB and RPVTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Cohorts Part A, C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Area under the concentration - time curve from time zero to last quantifiable time point or 8 weeks following the injection whichever is earlier [AUC(0-t)]Time frame: Up to end of study (Week 72 for Cohort C10 and C12 [Part C])
- Plasma Concentration of CAB and RPV at Week 4Time frame: Week 4
- Plasma Concentration of CAB and RPV at Week 8Time frame: Week 8
- Plasma Concentration of CAB and RPV at Week 12Time frame: Week 12
- Plasma Concentration of CAB and RPV at Week 16Time frame: Week 16
- Plasma Concentration of CAB and RPV at Week 24Time frame: Week 24
- Plasma Concentration of RPV at Week 32Time frame: Week 32
- Plasma Concentration of CAB at Week 36Time frame: Week 36
- Plasma Concentration of RPV at Week 40Time frame: Week 40
- Plasma Concentration of CAB and RPV at Week 48Time frame: Week 48
- Plasma Concentration of CABTime frame: At weeks 56, 64 and 72 for Cohorts C10, C11 and C12 [Part C]
- Plasma Concentration of RPV at Week 56Time frame: Week 56
- Plasma Concentration of RPV at Week 64Time frame: Week 64
- Plasma Concentration of RPV at Week 72Time frame: Week 72
- Apparent terminal phase half-life (t1/2) of CAB and RPVTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Apparent long-acting absorption rate constant (KA-LA) of CAB and RPVTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Number of Participants with Non-serious Adverse Events (non-SAEs) and Serious Adverse Events (SAEs)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Number of Participants with AEs by SeverityTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Absolute value of hematology parameter: Platelet count (cells per microliter)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Absolute values of hematology parameters: Reticulocytes (Percentage of reticulocytes)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Absolute values of hematology parameters: Hematocrit (Proportion of red blood cells in blood)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Absolute values of hematology parameters: Hemoglobin (Hgb) (grams per deciliter)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C] , and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Absolute value of hematology parameter: Red Blood Cell Count (RBC) (million cells per microliter)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Absolute value of hematology parameter: Mean Corpuscle Volume (MCV) (Femtoliters)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Absolute value of hematology parameter: Mean Corpuscle Hemoglobin (MCH) (Picograms)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Absolute values of hematology parameters: Differential count of Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per liter)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Absolute values of Clinical Chemistry parameters: Glucose (fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per deciliter)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Absolute values of Clinical Chemistry parameters: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per liter)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Absolute values of Clinical chemistry parameters: Albumin and Total Protein (Grams per deciliter)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Change from Baseline in hematology parameter: Platelet count (cells per microliter)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Change from Baseline in hematology parameters: Reticulocytes (Percentage of reticulocytes)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Cohorts Part A, C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Change from Baseline in hematology parameters: Hematocrit (Proportion of red blood cells in blood)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Change from Baseline in hematology parameters: Hgb (grams per deciliter)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Change from Baseline in hematology parameter: RBC Count (million cells per microliter)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Change from Baseline in hematology parameter: MCV (Femtoliters)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Change from Baseline in hematology parameter: MCH (picograms)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Change from Baseline in hematology parameters: Differential count of Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (Giga cells per liter)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Change from Baseline in Clinical Chemistry parameters: Glucose (fasting), BUN, Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per deciliter)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Change from Baseline in Clinical Chemistry parameters: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per liter)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Change from Baseline in Clinical chemistry parameters: Albumin and Total Protein (Grams per deciliter)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
- Number of participants with maximum toxicity grades increase from Baseline in hematology and clinical chemistryTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Orlando, Florida · Completed
GSK Investigational Site
Las Vegas, Nevada · Recruiting
GSK Investigational Site
Austin, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.